Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen December 28, 2021 by Businesswire [#item_full_content] Related Spread the word
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish